Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis

Hiroyuki Takemura, Hiroshi Suzuki, Kazuyuki Yoshizaki, Atsushi Ogata, Takamichi Yuhara, Takao Akama, Kazuhide Yamane, Heihachiro Kashiwagi

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective. To investigate the presence and the roles of anti-interleukin-6 (anti-IL-6) autoantibodies in rheumatic diseases, and to further elucidate clinical and pathophysiologic significance of anticytokine autoantibodies. Methods. Anti-IL-6 IgG autoantibodies were measured by the 125I-IL-6 binding activity of IgG, which was isolated from serum by protein A-Sepharose. Results. Nine of 52 sera (17.3%) from patients with systemic sclerosis (SSc) contained anti-IL-6 antibodies, whereas only 1.9% of sera from normal subjects and 0-5% of sera from patients with other rheumatic diseases were positive for the antibodies. Moreover, anti-IL-6 autoantibodies were found predominantly among patients with the limited form of SSc (42.9%), compared with those with the diffuse form (7.9%). Conclusion. Anti-IL-6 IgG autoantibodies were detected in patients with SSc, particularly those with the limited form of the disease, at a significantly increased frequency compared with normal subjects and patients with other rheumatic diseases. These results suggest that the development of anti-IL-6 autoantibodies and IL-6 may have a role in the pathophysiology of SSc.

Original languageEnglish
Pages (from-to)940-943
Number of pages4
JournalArthritis and Rheumatism
Volume35
Issue number8
Publication statusPublished - 1992 Aug
Externally publishedYes

Fingerprint

Systemic Scleroderma
Rheumatic Diseases
Autoantibodies
Interleukin-6
Serum
Immunoglobulin G
Antibodies
Blood Proteins

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Takemura, H., Suzuki, H., Yoshizaki, K., Ogata, A., Yuhara, T., Akama, T., ... Kashiwagi, H. (1992). Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis. Arthritis and Rheumatism, 35(8), 940-943.

Anti-interleukin-6 autoantibodies in rheumatic diseases : Increased frequency in the sera of patients with systemic sclerosis. / Takemura, Hiroyuki; Suzuki, Hiroshi; Yoshizaki, Kazuyuki; Ogata, Atsushi; Yuhara, Takamichi; Akama, Takao; Yamane, Kazuhide; Kashiwagi, Heihachiro.

In: Arthritis and Rheumatism, Vol. 35, No. 8, 08.1992, p. 940-943.

Research output: Contribution to journalArticle

Takemura, H, Suzuki, H, Yoshizaki, K, Ogata, A, Yuhara, T, Akama, T, Yamane, K & Kashiwagi, H 1992, 'Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis', Arthritis and Rheumatism, vol. 35, no. 8, pp. 940-943.
Takemura, Hiroyuki ; Suzuki, Hiroshi ; Yoshizaki, Kazuyuki ; Ogata, Atsushi ; Yuhara, Takamichi ; Akama, Takao ; Yamane, Kazuhide ; Kashiwagi, Heihachiro. / Anti-interleukin-6 autoantibodies in rheumatic diseases : Increased frequency in the sera of patients with systemic sclerosis. In: Arthritis and Rheumatism. 1992 ; Vol. 35, No. 8. pp. 940-943.
@article{dde01846a49e47b280c2c62d49f127e2,
title = "Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis",
abstract = "Objective. To investigate the presence and the roles of anti-interleukin-6 (anti-IL-6) autoantibodies in rheumatic diseases, and to further elucidate clinical and pathophysiologic significance of anticytokine autoantibodies. Methods. Anti-IL-6 IgG autoantibodies were measured by the 125I-IL-6 binding activity of IgG, which was isolated from serum by protein A-Sepharose. Results. Nine of 52 sera (17.3{\%}) from patients with systemic sclerosis (SSc) contained anti-IL-6 antibodies, whereas only 1.9{\%} of sera from normal subjects and 0-5{\%} of sera from patients with other rheumatic diseases were positive for the antibodies. Moreover, anti-IL-6 autoantibodies were found predominantly among patients with the limited form of SSc (42.9{\%}), compared with those with the diffuse form (7.9{\%}). Conclusion. Anti-IL-6 IgG autoantibodies were detected in patients with SSc, particularly those with the limited form of the disease, at a significantly increased frequency compared with normal subjects and patients with other rheumatic diseases. These results suggest that the development of anti-IL-6 autoantibodies and IL-6 may have a role in the pathophysiology of SSc.",
author = "Hiroyuki Takemura and Hiroshi Suzuki and Kazuyuki Yoshizaki and Atsushi Ogata and Takamichi Yuhara and Takao Akama and Kazuhide Yamane and Heihachiro Kashiwagi",
year = "1992",
month = "8",
language = "English",
volume = "35",
pages = "940--943",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Anti-interleukin-6 autoantibodies in rheumatic diseases

T2 - Increased frequency in the sera of patients with systemic sclerosis

AU - Takemura, Hiroyuki

AU - Suzuki, Hiroshi

AU - Yoshizaki, Kazuyuki

AU - Ogata, Atsushi

AU - Yuhara, Takamichi

AU - Akama, Takao

AU - Yamane, Kazuhide

AU - Kashiwagi, Heihachiro

PY - 1992/8

Y1 - 1992/8

N2 - Objective. To investigate the presence and the roles of anti-interleukin-6 (anti-IL-6) autoantibodies in rheumatic diseases, and to further elucidate clinical and pathophysiologic significance of anticytokine autoantibodies. Methods. Anti-IL-6 IgG autoantibodies were measured by the 125I-IL-6 binding activity of IgG, which was isolated from serum by protein A-Sepharose. Results. Nine of 52 sera (17.3%) from patients with systemic sclerosis (SSc) contained anti-IL-6 antibodies, whereas only 1.9% of sera from normal subjects and 0-5% of sera from patients with other rheumatic diseases were positive for the antibodies. Moreover, anti-IL-6 autoantibodies were found predominantly among patients with the limited form of SSc (42.9%), compared with those with the diffuse form (7.9%). Conclusion. Anti-IL-6 IgG autoantibodies were detected in patients with SSc, particularly those with the limited form of the disease, at a significantly increased frequency compared with normal subjects and patients with other rheumatic diseases. These results suggest that the development of anti-IL-6 autoantibodies and IL-6 may have a role in the pathophysiology of SSc.

AB - Objective. To investigate the presence and the roles of anti-interleukin-6 (anti-IL-6) autoantibodies in rheumatic diseases, and to further elucidate clinical and pathophysiologic significance of anticytokine autoantibodies. Methods. Anti-IL-6 IgG autoantibodies were measured by the 125I-IL-6 binding activity of IgG, which was isolated from serum by protein A-Sepharose. Results. Nine of 52 sera (17.3%) from patients with systemic sclerosis (SSc) contained anti-IL-6 antibodies, whereas only 1.9% of sera from normal subjects and 0-5% of sera from patients with other rheumatic diseases were positive for the antibodies. Moreover, anti-IL-6 autoantibodies were found predominantly among patients with the limited form of SSc (42.9%), compared with those with the diffuse form (7.9%). Conclusion. Anti-IL-6 IgG autoantibodies were detected in patients with SSc, particularly those with the limited form of the disease, at a significantly increased frequency compared with normal subjects and patients with other rheumatic diseases. These results suggest that the development of anti-IL-6 autoantibodies and IL-6 may have a role in the pathophysiology of SSc.

UR - http://www.scopus.com/inward/record.url?scp=0026690770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026690770&partnerID=8YFLogxK

M3 - Article

C2 - 1642659

AN - SCOPUS:0026690770

VL - 35

SP - 940

EP - 943

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -